ArcherDx
Dx Industry M&A Activity Jumps in 2020 Driven by Promising Genetic Testing, Cancer Players
Illumina's acquisition of Grail, Exact Sciences' acquisition of Thrive Earlier Detection, and Invitae's acquisition of ArcherDx all topped out at over $1 billion.
Invitae Q3 Revenues Increase 22 Percent
The firm generated $68.7 million in revenues compared to $56.5 million in Q3 2019 and exceeded the consensus Wall Street estimate.Â
Natera Sues Genosity for Patent Infringement Relating to ArcherDx Products
Natera claims that several Genosity products infringe its US Patent No. 10,732,220, titled "Methods for Simultaneous Amplification of Target Loci."
Federal Court Rejects ArcherDx Motion Against Natera in Patent Infringement Lawsuit
Last month, the court also ordered two separate patent lawsuits filed by Natera against ArcherDx this year to be consolidated into one.
Invitae Completes Acquisition of ArcherDx
The merger brings tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings.
Jun 7, 2020
ArcherDx Targeting $100M in IPO
Jan 10, 2020
ArcherDx, Illumina Agree to Comarket Future IVDs
Dec 17, 2019